1Life Healthcare, Inc.

ONEM Details

One Medical Begins Vaccinating for COVID-19: 1Life Healthcare, Inc. (NASDAQ: ONEM) is mainly involved in the business of services-offices and clinics of doctors of medicine. The company provides administrative and managerial services for the affiliated One Medical physician-owned professional corporations. Notably, 1Life and the One Medical entities operate under the “One Medical” brand. Recently, One Medical started administering vaccinations for Phase 1a populations who work or live in San Francisco. It is also proceeding to start vaccinations in other markets as well.

Q3FY20 Result Highlights: For Q3FY20, the company reported total revenue of $101.7 million, up 46% on pcp. During the quarter, the company’s total membership count reached 511,000. Further, the company reported adjusted EBITDA of $3.5 million and a net loss of $16.4 million. The company ended the quarter with cash and short-term marketable securities of $682.3 million.

Q3FY20 Result Highlights (Source: Company Reports)

Outlook: With its technology platform, operations infrastructure, and clinical team, One Medical seems well placed to support broad COVID-19 vaccine efforts in markets across the country. For Q4FY20, the company expects its total revenue to be between $104 million and $109 million. Further, the adjusted EBITDA is expected to be in the range of an EBITDA loss of $4 million to positive $1 million. For FY20, the company expects total revenue to be between $362 million and $367 million. Adjusted EBITDA for FY20 is expected to be in the range of a loss of $29 million to a loss of $24 million.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation (Illustrative)

EV/Sales Multiple Based Relative Valuation (Source: Refinitiv, Thomson Reuters)

Note: All the forecasted figures are taken from Thomson Reuters, NTM: Next Twelve Months

Stock Recommendation: Over the last three months, the stock of ONEM has provided a return of 45.89% and is trading close to its 52-week high of $44.87. On the technical analysis front, the stock has a support level of ~$38.41 and resistance of ~$44.29. We have valued the stock using an EV/Sales multiple based illustrative relative valuation method and arrived at a target price with a correction of low single-digit (in % terms). For the purpose, we have taken peers like Accolade Inc (NASDAQ: ACCD), Phreesia Inc (NYSE: PHR), and Oak Street Health, Inc. (NYSE: OSH). Considering the decent returns in the last three months, current trading level and valuation, we suggest investors to book profit and give a “Sell” rating on the stock at the closing price of $42.63, down by 2.34% as on 4 January 2021.

ONEM Daily Technical Chart (Source: Refinitiv, Thomson Reuters)

Disclaimer

PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS.

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated.

Kalkine do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser.